SCHEMBL27383269

SCHEMBL27383269

CC(C)c1cc2[nH]c(CNC(=O)C3CCC3)cc2cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.56
▸ MTNR1A P48039 1/20 0.48
▸ MTNR1B P49286 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HPGD P15428 4/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ USP2 O75604 1/20 0.38
▸ PTGES O14684 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ IDH1 O75874 1/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ ERCC1 P07992 1/20 0.35
▸ ERCC4 Q92889 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27385036 0.86 RAB9A (0.43) RAB9AMTNR1AMTNR1BSMN1; SMN2IDH1
SCHEMBL27385039 0.85 RAB9A (0.42) RAB9AMTNR1AMTNR1BSMN1; SMN2HPGD
SCHEMBL27385399 0.84 PKM (0.47) RAB9ASMN1; SMN2HPGDALDH1A1GAA
SCHEMBL27385164 0.83 RAB9A (0.41) RAB9AMTNR1AMTNR1BSMN1; SMN2HTT
SCHEMBL27384178 0.82 SMN1; SMN2 (0.42) RAB9ASMN1; SMN2HPGDHTTPOLB
SCHEMBL27383268 0.82 RAB9A (0.61) RAB9AMTNR1AMTNR1BSMN1; SMN2HPGD
SCHEMBL27383728 0.82 RAB9A (0.53) RAB9AMTNR1AMTNR1BSMN1; SMN2HPGD
SCHEMBL27384491 0.80 SMN1; SMN2 (0.43) RAB9AMTNR1AMTNR1BSMN1; SMN2HTT
SCHEMBL27382675 0.80 MTNR1A (0.44) RAB9AMTNR1AMTNR1BSMN1; SMN2HPGD
SCHEMBL27383947 0.79 RAB9A (0.55) RAB9AMTNR1AMTNR1BSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed
Send feedback